Art Krieg, Checkmate CSO
IPO bound? Five years in, Art Krieg and the Checkmate crew collect $85M to back up their 1-drug pipeline
Five years after Art Krieg picked up a drug to make a bid in the feverish immuno-oncology space with a startup called Checkmate Pharmaceuticals, he …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
